Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BAY 3283142 in Renal Impairment
NCT05515432Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAY3283142 in chronic kidney disease (CKD) (5 arms), sponsored by Bayer. Primary endpoints: Area Under the Curve, Unbound Area Under the Curve and 2 more. Started Aug 2022; status: completed.
02
Drugs
BAY3283142
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05515432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515432.